Managing multiple myeloma treatment side effects: urgent symptoms and continuing care

Managing adverse effects helps patients receive treatment under conditions they can tolerate. Symptoms should not be hidden out of fear that the doctor will stop an effective medicine. They should also not automatically be attributed to the prescription: myeloma, infection, anemia and fractures can produce similar problems. Timing, examination, tests and the exact medicines are needed to distinguish causes. This guide was checked in September 2026 for patients arranging treatment and follow-up in China.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Fever during treatment, especially with chills, marked weakness or low blood counts, needs prompt contact with the clinical team. NCI lists 38°C or above among signs of possible infection. Severe breathlessness, chest pain, altered awareness, inability to stand or persistent bleeding should not wait for a routine appointment. Serious deterioration can also occur without a high temperature. The NCI infection and neutropenia information explains the need for urgent assessment.
Myeloma, reduced mobility and some treatment combinations increase venous thrombosis risk. A swollen painful leg or sudden chest pain and breathlessness needs evaluation. The 2025 European Myeloma Network thrombosis guideline emphasizes repeated risk assessment, education and individualized prevention rather than a single prescription for everyone.
Write down when a symptom began, its interval from treatment, severity, effect on activities, attempted management and whether it improved. Add temperature, weight or blood-pressure measurements when the team has requested them. Record changes after dose modification too. The objective is useful information, not constant self-testing that consumes the patient's day.

Quick answer

Full guide

Treat concerning fever, breathing difficulty and confusion as urgent problems

Fever during treatment, especially with chills, marked weakness or low blood counts, needs prompt contact with the clinical team. NCI lists 38°C or above among signs of possible infection. Severe breathlessness, chest pain, altered awareness, inability to stand or persistent bleeding should not wait for a routine appointment. Serious deterioration can also occur without a high temperature. The NCI infection and neutropenia information explains the need for urgent assessment.

A lower temperature after an antipyretic does not exclude infection. Do not merely suppress symptoms and continue traveling or take leftover antibiotics without assessment. Before discharge, obtain daytime and overnight contact routes and identify a nearby emergency service. International patients should carry the latest treatment date and blood results so that emergency clinicians know more than the fact that cancer treatment is underway.

Match infection prevention to the actual regimen

Infection risk reflects myeloma, previous treatments and current therapy. Antiviral prevention, pneumocystis prophylaxis, vaccination and immunoglobulin replacement require an individualized plan. Bispecific-antibody recipients can remain vulnerable after the initial dosing period because low immunoglobulins and cytopenias may persist. The bispecific infection-management consensus provides specific recommendations.

Ask what each preventive medicine is intended to prevent, what monitoring it needs and when it can be stopped. Hand hygiene, catheter care and avoiding close contact with someone who is infectious are useful but do not replace prescribed prevention. Low immunoglobulin results are also not an instruction to obtain an infusion independently; the indication, product and risks need clinical review.

Understand which blood cells have fallen

Neutropenia affects infection defense, low platelets increase bleeding risk and anemia can cause fatigue, palpitations or breathlessness. They are managed differently. The team considers the value, trend, symptoms and planned treatment before deciding on support, delay or dose modification. The IMWG infection-prevention consensus places blood counts within a wider risk assessment.

Know the next blood-test date and which symptoms require earlier contact. Increasing bruises, persistent nosebleeds, black stools or blood in urine deserve attention, especially when anticoagulants are also prescribed. Do not stop the entire medication list or substitute supplements for laboratory monitoring. Activity may need adaptation to bleeding and fall risk, with the aim of preserving function safely.

Report neuropathy through its effect on daily tasks

Bortezomib-related peripheral neuropathy can cause tingling, burning, numbness or weakness. Record symptoms already present before treatment. New difficulty walking, reduced sensation in the feet or trouble with fine hand movements should be described early. The clinician may alter the dose, route or schedule rather than only adding pain medicine. These options appear in the bortezomib prescribing information.

Back pain with new leg weakness should not simply be labeled peripheral neuropathy; spinal disease may require urgent assessment. Explain where symptoms occur and their relationship to treatment dates. Protect areas with reduced sensation from excessive heat, and avoid manipulation of a spine known to have a fracture or instability. Improvement does not authorize the patient to restore a previous drug dose without review.

Monitor cardiovascular and fluid changes separately

Carfilzomib requires attention to cardiac, blood-pressure and kidney risks. New exertional breathlessness, difficulty lying flat, swelling, reduced urine output or a marked short-term weight increase should be reported, with emergency assessment for severe symptoms. Hydration must take cardiac as well as renal status into account. The carfilzomib label describes these warnings.

If home blood-pressure, weight or fluid records are advised, obtain the method, frequency and thresholds for contacting the team. Another patient's fluid target may be inappropriate, particularly in dialysis or heart failure. Chest symptoms can reflect several conditions; patients need not identify the cause before seeking help. An accurate account of the symptoms and current medicines is more useful.

Balance clot prevention against bleeding risk

Myeloma, reduced mobility and some treatment combinations increase venous thrombosis risk. A swollen painful leg or sudden chest pain and breathlessness needs evaluation. The 2025 European Myeloma Network thrombosis guideline emphasizes repeated risk assessment, education and individualized prevention rather than a single prescription for everyone.

Platelet count, kidney function and bleeding history influence preventive treatment with regimens containing medicines such as lenalidomide. When prescriptions or brands change during care in China, check the anticoagulant plan as well. Before a long flight, ask for a renewed assessment rather than increasing anticoagulation independently. A diagnosed clot requires its own treatment and travel plan.

Immune-treatment reactions need clinical assessment

Cellular treatments and bispecific antibodies can cause cytokine release syndrome and neurological toxicity. Fever, low blood pressure, low oxygen levels, language difficulty, unusual drowsiness or behavioral change should be assessed using the treating center's pathway. Infection may coexist. Relatives can help by recognizing changes from the person's usual communication and behavior. The FDA teclistamab information identifies these major risks.

The US removed REMS requirements for the then-approved relevant autologous CAR-T products in 2025, but this did not remove toxicity or the need for monitoring. The FDA announcement retains labeling warnings and long-term safety oversight. Chinese institutional qualifications, observation periods and discharge criteria follow the actual local product and service, rather than being determined by that US policy change.

Persistent gastrointestinal symptoms have several possible causes

Diarrhea can result from medicine, infection or another digestive disorder. With selinexor, nausea, inadequate intake, dehydration and low sodium also require attention. Antiemetic preparation and electrolyte monitoring belong in the plan. The selinexor label provides the monitoring basis. Persistent vomiting, pronounced drowsiness or inability to drink should prompt care rather than improvised salt replacement.

After cilta-cel, severe or prolonged diarrhea, abdominal pain and weight loss developing weeks to months later can indicate immune effector cell-associated enterocolitis. The FDA added a boxed warning in 2025. Clinicians must assess infection and other causes rather than treating every episode as routine gastroenteritis. The FDA enterocolitis communication highlights this delayed risk, making the cellular-treatment history important after the patient returns home.

Eye, mouth and skin effects can limit treatment

Belantamab-related corneal and visual changes require scheduled eye assessment, including when the patient has little subjective discomfort. Report blurred vision and discuss driving or other activities with the team. The FDA belantamab combination information emphasizes ocular toxicity.

Talquetamab can affect taste, saliva, swallowing, skin and nails, with consequences for nutrition and daily life. Record what foods remain tolerable, weight changes and any reduction in activity caused by symptoms. The FDA talquetamab announcement describes these effects. Seek help before weight loss becomes severe; topical treatments and nutritional support should be selected for the actual problem and regimen.

Bone-protective medicines also require monitoring

Denosumab carries risks of hypocalcemia and osteonecrosis of the jaw. Severe kidney impairment and dialysis make low calcium particularly relevant. Baseline dental assessment, reporting a nonhealing gum area or jaw pain, and telling the dentist about treatment are practical safeguards. The denosumab prescribing information describes these warnings.

Calcium and vitamin D recommendations must consider current calcium and renal results, because myeloma can itself cause high calcium. Coordinate extractions or other invasive dental procedures with the hematology team. Do not independently stop treatment or assume that risk ends after an injection. Perioral numbness or muscle cramps should be reported and assessed rather than assigned a cause at home.

Bring a symptom record that supports a decision

Write down when a symptom began, its interval from treatment, severity, effect on activities, attempted management and whether it improved. Add temperature, weight or blood-pressure measurements when the team has requested them. Record changes after dose modification too. The objective is useful information, not constant self-testing that consumes the patient's day.

During treatment in China, confirm how the service coordinates infectious-disease, cardiac, eye, renal or dental assessment when needed. The budget may need to include extra investigations, admissions and supportive treatment. Before leaving, obtain an updated medication list, abnormal results, reasons for interruptions and the receiving clinician's contact. Dose reduction does not necessarily erase benefit, and disappearance of a symptom does not authorize independent dose escalation. Timely reporting and evidence-based adjustment help make treatment sustainable.